Shares of Biotechnology company Revolution Medicines jumped 4.5% today. With many investors piling into RVMD without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:
-
Revolution Medicines has moved 42.3% over the last year, and the S&P 500 logged a change of 28.4%
-
RVMD has an average analyst rating of buy and is -24.05% away from its mean target price of $59.62 per share
-
Its trailing earnings per share (EPS) is $-3.72
-
Revolution Medicines has a trailing 12 month Price to Earnings (P/E) ratio of -12.2 while the S&P 500 average is 28.21
-
Its forward earnings per share (EPS) is $-3.84 and its forward P/E ratio is -11.8
-
The company has a Price to Book (P/B) ratio of 4.63 in contrast to the S&P 500's average ratio of 4.71
-
Revolution Medicines is part of the Health Care sector, which has an average P/E ratio of 27.61 and an average P/B of 3.69
-
The company has a free cash flow of $-281241984, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
